Skip to main navigation Skip to search Skip to main content

Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

  • Laure Vincent
  • , Luuk Gras
  • , Patrice Ceballos
  • , Jürgen Finke
  • , Jakob Passweg
  • , Stéphanie Harel
  • , Laura Rosinol
  • , Monique Minnema
  • , Raphael Teipel
  • , Jaap van Doesum
  • , Mathias Hänel
  • , Pascal Lenain
  • , Carmen Botella-Garcia
  • , Christian Koenecke
  • , Sophie Ducastelle
  • , Jaime Sanz
  • , Wilfried Schroyens
  • , Tsila Zuckerman
  • , Federico Monaco
  • , Linda Koster
  • Liesbeth de Wreede, Patrick J Hayden, Stefan Schönland, Ibrahim Yakoub-Agha, Meral Beksac

Research output: Contribution to journalLetterAcademicpeer-review

Original languageEnglish
Pages (from-to)499-501
Number of pages3
JournalBone Marrow Transplantation
Volume57
Issue number3
Early online date10 Jan 2022
DOIs
Publication statusPublished - Mar 2022

Cite this